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Abstract
Among the numerous infectious diseases, malaria still remains the main cause of 
morbidity and mortality across the world. Every year more than 200 million cases are 
registered and death toll is of around 4,00,000. The emergence of insecticide and 
drug resistance has surged an alarming situation to find an effective means to tackle 
it. From various approaches used for reducing the damage created by malaria to the 
society, developing effective vaccine has gained the attention of scientific community. 
The large genome size (24 MB), heterogeneity of the genes, complex life cycle in two 
different hosts, and expression of wide range of these genes are claimed to hinder the 
malaria vaccine development. It requires good understanding of the host-pathogen 
interaction and its correlation with the sterile protection. Recently, subunit vaccine 
have shown certain promising responses; however, the currently in use of RTS,S vac-
cine has failed to generate the long-term sterile protection as well as effector memory 
CD8+T cells. However, the success of sterile protection through vaccination has been 
proven long back by experimental approaches, where it could be achieved using irra-
diated sporozoites (RAS) in rodents and humans. Similarly, GAP (genetically attenu-
ated parasite) and CPS (chloroquine chemoprophylaxis with Plasmodium sporozoites) 
have been shown to induce sterile immunity. Despite all the developments, generation 
of species and stage specific-CD8+ T cell responses has been modest. In order to 
generate long-lasting immune response, particularly, liver-stage specific-CD8+ T cells, 
it is indeed required to study the CD8+ T cell epitope repertoire and its implications 
on the host immune system. In this chapter we will discuss the current status of T cell-
based vaccines and the challenges associated with it.
Keywords: Malaria, subunit vaccine, CD8+ T cells response, sterile immunity, 
memory T cells
1. Introduction: Malaria pathogenesis
Since the origin of Homo sapience through the continuous evolution process, we 
have become the most successful creature on the Earth by maintaining the symbi-
otic relation with other species to live freely. On the other hand, there are several 
tiny, single/multi-cellular organisms which may not be possible to see by naked 
eye have created the threat for us and we have witnessed the long-fight to fulfill 
the basic principle of Survival of the fittest. Underneath all these tiny organisms, a 
group of species falls under the category of an infection, an invasion process through 
which they enter into the host system, and follow the multiplication/replication 
process that results in the release of toxins inside the body [1]. From the list of 
myriad infectious diseases, malaria caused by Plasmodium species (a parasite of 
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Apicomplexa phylum) and transmitted through the bite of Anopheles female mos-
quitoes, still persists as the leading cause of morbidity and mortality [2, 3]. As per 
the latest World Malaria Report 2020, there are 229 million cases registered in more 
than 87 countries across the globe in 2019; it was 238 million in the year of 2000. 
Malaria is considered a life-threatening disease as the mortality rate is still higher, 
and estimated 409,000 death were reported in the last year [2]. Today half of the 
population lives under the risk of malaria infection and it has mainly affected the 
South-African region which is responsible for more than 94% cases in 2019 followed 
by South-East Asia and Western pacific region (Figure 1).
Despite the reduction in the malaria mortality rate (from 25% in 2000 to 10% in 
2019), the children under the age of 5 years are the most vulnerable group (due to 
the lack of adequate acquired immunity) as 67% of total death in 2019 was reported 
in this group. Likewise, pregnant women are also at the higher risk as it quells the 
immune system [2, 4]. Athwart the other Apicomplexa parasites having the com-
modious range of metazoans for the infection, Plasmodium species have a restricted 
range in terms of specificity for insect and vertebrate hosts [5]. In humans, malaria 
is mainly caused by four Plasmodium species and, P. falciparum is responsible for 
the most severity as it has been accounted for more than 70% cases across the 
world (more prominent in African region-99.7%) in 2018 [2, 6] whereas, P. vivax 
is responsible for malaria infection in American region (75%) followed by South 
East Asia [2, 7, 8]. Other species, known as P. ovale [9] and P. malariae [10] are also 
responsible for the malaria infection, yet the complications are less. Recently, P. 
knowlesi is found to infect humans in Malaysia [11] however, the host specificity is 
not limited to the humans as reports of infection are also reported in monkeys [10].
The Plasmodium species carries the complex life cycle consist of two hosts: 
Anopheles mosquitoes (sexual cycle) and human (asexual cycle). The cycle begins 
with the bite of infected female Anopheles mosquitoes to the human during the 
blood meal and transfers sporozoites [12] into the skin. They remain at the inocula-
tion site for a short time and further travel to the liver where they invade the liver 
hepatocytes. Inside the liver by tight regulation and signaling mechanism, they 
select the hepatocytes, invade them and mature into the schizonts. This phase of 
Figure 1. 
Countries with indigenous cases in 2000 and their status by 2019: Countries with zero indigenous cases over at 
least the past 3 consecutive years are considered to have eliminated malaria. In 2019, China and El Salvador 
reported zero indigenous cases for the third consecutive year and have applied for WHO certification of 
malaria elimination; also, the Islamic Republic of Iran, Malaysia and Timor-Leste reported zero indigenous 
cases for the second time. Source: WHO database (adapted with permission from [2]).
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cycle is also known as pre-erythrocytic stage [13]. Further, these schizonts rupture 
and release merozoites which come out and infect the erythrocytes (RBCs). 
However, P. vivax and P. ovale remain in the dormant stage in the liver for a pro-
longed period of time if left untreated and may relapse after several years. Once the 
merozoites pop-up in the blood stream, they infect the RBCs which further divide, 
replicate and passes through several developmental stages, ring stage-trophozoite 
stage-schizont formation in chronological order, and ended up in release of count-
less merozoites. These merozoites further infect the new RBCs and cycle continues. 
During this erythrocytic stage (or blood stage), a number of trophozoites develop 
into male (micro) and female (macro) gametocytes [13]. The mature gametocytes 
migrate towards the dermis of skin; during the next blood meal of vector mos-
quitoes, they are taken-up by the mosquitoes. Formation of zygotes takes place by 
fertilization of micro and macro gametes in the stomach of Anopheles mosquito. 
Later, these zygotes are converted into the motile ookinetes which finally develop 
into the oocytes and rupture the mid-gut [13]. These oocytes evolve, unfold and 
materialize into sporozoites, which subsequently reach to the salivary gland of the 
mosquito and ready for the next cycle in human host. The phase of conversion of 
asexual gametocytes into mature sporozoites is also known as sporogonic cycle [13]. 
Figure 2 depicts the basic malaria life cycle of P. falciparum.
Figure 2. 
The P. falciparum life-cycle. An infected female Anopheles mosquito inoculates Spz as it bites a host, they then 
travel in the host’s bloodstream and infect the hepatocytes. Merozoites are released and then invade erythrocytes, 
where they mature through various stages (ring, trophozoite and schizont stages) and undergo asexual 
multiplication (~ 10 or lower) every 48 h, releasing new merozoites which perpetuate the asexual cycle. Some of 
them enter the sexual cycle by becoming female and male gametocytes which are ingested by the mosquito when 
it bites an infected host, thereby starting the cycle all over again (adapted with permission from [14]).
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2. Malaria elimination and eradication: Grasping at straws
It was 1897 when Ronald Ross has identified the parasites responsible for the 
malaria infection and later on the development in the field of science and technol-
ogy has opened up several areas to work upon and eliminate the malaria infection 
[15]. The basic understanding of epidemiology and entomology, host-pathogen 
interaction, surveillance and numerous studies have provided the information 
about the usage of two main prophylactic methods to curtail down the morbidity 
and mortality spread by malaria infection: prevention of infection and diseases by 
controlling the mosquitoes and usage of antimalarial therapy, respectively. As per 
the recommendation by WHO, insecticides-treated nets (ITNs) have been used 
to prevent the insect from reaching out the humans. Nonetheless, the results were 
discouraging as less than 2% children were protected in African region through the 
usage of ITNs [16]. Further, to surpass the limitation of ITNs, spraying of various 
insecticides (such as DDT, permethrin, deltamethrin, pyrethriods) have come into 
the practice, although it has only cover the tip of the iceberg [17]. To strengthen the 
above approaches WHO has launched the global malaria eradication program in 
early 1955 [18] and DDT & chloroquine have been recommended for the ITNs and 
prevention and treatment of infection, respectively [19]. Despite significant reduc-
tion in several developing and underdeveloped countries, the reports of Plasmodium 
resistance against the chloroquine and Anopheles resistance towards the DDT 
forced WHO to abandon the program in 1972 [20, 21]. Thereupon, several other 
approaches have been implemented for vector controls. However, the reports of 
insecticide resistance against almost all the Anopheles vector and resistance against 
1-out-of 5 publicly used nets in more than 68 countries have created alarming situ-
ation [22]. Further, out of these 68 countries, more than 50 countries have shown 
the resistance against more than two or more insecticides which has added the fuel 
to the fire [22, 23]. To tackle the situation of resistance, noninsecticidal approach 
of bacterial endosymbionts [24], long-lasting insecticides nets (LLINs) and LLINs 
treated hammocks [25] are under development.
Likewise, the drug resistance against the frontline antimalarial drug quinine has 
forced the mankind to use the other drugs and combination. However, the reports 
of resistance against the artemisinin in Greater Mekong Subregion (GMK) in a short 
span of its launch [26] and unavailability of other options for artemisinin combina-
tion therapy (ACT) have invoked the bleak condition for the treatments [27]. To 
prevail the condition of drug resistance, scientist have opted for mass drug admin-
istration (MDA) approach in which antimalarial drugs have been recommended to 
the specific group of people without getting into the details of their illness. It has 
been further known as targeted malaria elimination (TME) [28, 29]. The results of 
this approach found to be satisfactory, however proper planning and management 
are the key factors for the success of MDA approach [15].
Apart from the well-known approaches, usage of antibiotics and their role to 
fight against the various diseases is widely accepted and therefore, azithromycin, 
doxycycline and clindamycin have been tested against the malaria. These antibiotics 
were found to be effective and also reached to the clinical phases; yet the delayed 
response is the major drawback due to which they cannot be utilized in mild-to-
severe and severe conditions of malaria [30]. Besides, a range of antibiotics named 
quinoloes, tetracycline, trimethoprim, erythromycin and others are in the early 
stage of development as they are showing promising results which kill the parasites 
[31], yet it has a long way to go.
Alongside the approaches used to control the malaria infection, human body 
also consists of a defense mechanism which respond according to the nature of 
threat (humoral and cell mediated immunity). It is believed that people living in 
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malaria endemic areas naturally develop immunity due to the continuous exposure 
of malaria infection. However, age, gender, geographical location, time (months to 
several years) and numerous other factors are considered to play a vital role in long-
term protection [32–34] against malaria. Despite the characteristics of developing 
protection against the malaria infection naturally, the poorly understood mecha-
nism and the long-term protection are controversial. Therefore, it is of utmost 
priority to gain the sterile protection against the malaria infection.
2.1 Approach of vaccine development: A ray of hope
Number of experimental approaches have been adopted to understand the 
Plasmodium species and provided us the immense knowledge about the host-
pathogen interaction, and how a parasite can escape and invade the immune system 
for its survival. It has been well documented that during the malaria infection, the 
protective response vis-a-vie humoral (antibody against malaria) and cell medi-
ated (CD4+ and CD8+ T cells) immunity is dampened [35]. Hence, to achieve the 
sterile protection against malaria infection, activation/boosting up the wings or full 
immune system is the fundamental target for any malaria biologist. In this direc-
tion, Nussenzwig and colleagues more than 53 years ago have used the approach of 
killed parasites of P. berghei to immunize the mice; however, they failed to generate 
the immune response. Therefore, approach of partial inactivation of sporozoites 
by X-irradiation has been used by them to achieve the protective immunity [36]. 
The observation of precipitation at one end of sporozoites and elevated level of 
the antibody (in serum) of the induced animals was correlated with the protective 
immunity. Further, they have observed the high level of antibody after each repeti-
tive dose.
After successful immunization strategy of X-irradiation in non-human host, 
Clyde et al., 1972 used the same approach for P. falciparum sporozoites and injected 
to the healthy volunteers frequently up-to 84 days, and on day 98 they were chal-
lenged with infectious sporozoites [37]. Out of three volunteers, one failed to 
develop the malaria infection and on day 327 anti-sporozoite antibodies were found. 
The result of this study has opened a new avenue for the vaccine development 
(usage of attenuated sporozoites) against the malaria. Later, they have extended the 
experiment by using two strains: P. falciparum and P. vivax and injected attenuated 
sporozoites [38]. The species-specific antibody formation and impact of the geo-
graphical location on the species were noticed. Also, the protection of immunized 
volunteers has found maximum for 3 and 6 months for the infectious sporozoites 
challenge of P. falciparum and P. vivax, respectively. Besides, they did not find 
any significant changes in the serum level of IgG and IgM [38]. In all, these data 
reveal the role of attenuated sporozoites in generating immune response specific 
to malaria, yet the long-term and species-specific immunity was remained to be 
unriddled. Regardless of the promising results of attenuated sporozoites approach, 
the tasks of rearing mosquitoes, maintaining the infection cycle and isolation 
of sporozoites are time-consuming, laborious and challenging. Besides, skilled-
personnel for appropriate functioning and injecting the live sporozoites are the 
pre-requisites for the successful vaccination. On the other side, the sustainability 
and higher-efficacy for the long term protection is found to be limited alongside the 
development of naturally acquired immunity against malaria [39, 40].
As discussed earlier, it is possible that people living in malaria endemic can 
develop naturally acquired immunity after prolonged exposure although it could 
be restricted to blood-stage infection. However, induction of immunity to liver-
stage (LS)infection among endemic population has not been thought to be possible 
because of lower infection load, heterogeneity of liver immunology of individuals 
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and characteristics which differ from blood stage [41]. Also, among the different 
stages of malaria infection, blocking the transmission of human-to-mosquitoes-to-
human and generation of modified mosquitoes may halt the spreading of malaria 
are in dire straits conditions. Similarly, to target particularly the infected RBCs 
containing merozoites and preventing them to infect other RBCs in the blood/
symptomatic stage has been very difficult. Nonetheless, the longest exposure of 
infected sporozoites towards the host immune system by invading hepatocytes in 
the liver stage (5.5 to 7 days in humans and 48 hrs in rodents) and releasing of thou-
sands of merozoites which further continue the blood-stage or symptomatic stage 
of infection makes the LS most promising stage for the target of vaccine develop-
ment [14, 42], though LS-vaccine has its own limitation of tedious and challenging 
task of sporozoites.
Taking into the above considerations, scientific community across the globe 
is working on multiple targets of different stages to tackle the dire condition. At 
present, there are mainly three types of vaccines based on the life-cycle: the liver 
(pre-erythrocytic) stage (LS), asexual blood (symptomatic) stage and the third one 
is transmission blocking vaccines (TBV).
2.1.1 History of malaria vaccine development
The successful experimental approach of using the attenuated sporozoites 
(P. berghei, P. knowlesi, P. falciparum, and P. vivax) in rodents and humans [43–47] 
including monkeys [48] to generate the sterile and protective immune responses 
have unfolded the newer therapeutic options. Likewise, development of humoral-
transmission blocking immunity in chicken and turkeys by immunizing killed-
asexual stage parasites [49], clearance of blood-stage infection in monkeys by 
arming the P. knowlesi asexual-parasites with adjuvants [50] and significant reduc-
tion in the P. falciparum blood-stage infection after passive transfer of immuno-
globulins from continuous exposure of malaria to naïve ones in humans [51–53] and 
monkeys [54] have excavated the different role of immune system. As stated above, 
work carried out by Clyde and colleagues corroborates the generation of protective 
immunity; however, requirement of large number of irradiated sporozoites was the 
biggest hassle. During the early 1980s, the breakthrough identification of circum-
sporozoite protein (CSP) as a major constituent of the sporozoite coat resulted 
into the sequencing and cloning of this gene followed by identification of several 
blood-stage antigens (Ags) led the world with the hope of early malaria vaccine 
[55]. Regardless of the CSP identification and other target Ags, approach of blood-
stage Ags, heat-killed, lysed and formalin inactivated sporozoites and sporozoites 
Ags in their early clinical studies have shown the moderate immune responses and 
unable to reach the threshold of immunity generated by irradiated sporozoites 
approach [55, 56].
The advancement in the field of sequencing helped in identifying the region 
of CSP protein having species-specific immunodominant epitope that consists of 
tandem repeated sequences of amino acids, Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-
Asn-Ala-Pro (NANP)3, remain conserved and found to be present in most of the 
people. The outcome of this work has led the pioneers to develop the approach of 
synthetic peptide. Upon synthesizing this specific epitope region (NANP)3 of CSP 
protein, several groups have conducted the experiments in monkeys and observed 
the partial or complete protection [57–59]. After having promising results in mon-
keys, SPf66 (a synthetic peptide based vaccine from Colombia) have been tested 
through independent trials in Asia and Africa; however, it was found ineffective in 
generating protection [60]. Despite the expected results of the SPf66, it has opened 
an avenue to study the immune response of other prominent vaccine candidates. 
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Several studies have revealed the important role of CSP protein in developing 
immunity during the sporozoite challenge studies and become the most promi-
nent candidate for the anti-malaria vaccine development [61]. However, the poor 
immunogenicity and lesser efficacy (in clinical trials) were the major concern to 
proceed further for CSP Ag. Therefore, Stoute et al., 1997 have used a novel formu-
lation of CSP Ag, known as RTS,S: a hybrid (fusion of CSP protein with hepatitis B 
surface Ag-HBs Ag) construct armed with novel adjuvants (AS02). The results were 
encouraging and also correlated with earlier studies [61]. This study led the founda-
tion for the first clinical trials in Africa (in Gambia). The RTS,S/AS02 was given to 
the men (N = 250 & age:18–45 years) and followed up to 15 weeks. It was found to 
be safe and actively producing CSP specific B-and-T cell responses and also protec-
tion was not limited only to the NF54 strain of P. falciparum from which the vaccine 
has been made [62]. In subsequent studies, the involvement of CD4+ and CD8+ T 
cells, sentinels of cellular immunity against the LS infection and role of Abs specific 
to the sporozoites have revealed the significant role of T- and B cells against malaria 
infection, respectively [63].
Further, parasite-specific Ags presented by MHC I and II to the CD8+ and CD4+ 
T cells, respectively on the surface of infected hepatocytes [64–68] delineate the 
importance of cell mediated immunity (CMI) to target the LS infection. All the 
above and other experimental evidences have unveiled the prominent role of CMI 
in generating sterile protection. As a result, it has changed the scenario in the field 
of vaccine development and to generate the sterile protection via boosting up CMI 
through a novel approach of plasmid DNA immunization. In the initial stage of 
development, Wang et al., 1998 have used the plasmid DNA bearing malaria Ag 
and injected into the malaria-naïve individuals. It has been shown to generate the 
Ag-specific, CD8+ cytotoxic T lymphocytes (CTLs); however, it was found to be 
genetically and HLA-restricted [69]. Regardless of restricted-CTL responses, this 
technology has driven the field and allowed to explore different suitable options 
to overcome the issue of poor immunogenicity of vaccine candidate(s) against 
malaria infection. To boost up the T-cell specific heterologous immune response, 
McConeky et al., 2003 have used the novel non-replicating viral vector (recombi-
nant modified vaccinia virus Ankara-MVA) approach. It has shown certain level 
of efficacy in terms of delayed parasitemia after the challenge with sporozoites. 
It induced five to ten fold elevated IFN-γ producing T-cells (specific-to-Ag) com-
pared to the plasmid DNA or recombinant MVA strategy, and the protection was 
independent of antibody response [70] creating the base for the preventive and 
therapeutic vaccine development. Thereafter, experimental results have confirmed 
that homologous or heterologous priming using viral vector approach could induce 
the CMI [71]. By using this approach, ME-TRAP, CSVAC (encodes PfCSP along-
side a truncated C-terminal lacking 14 amino acids of CSP GPI anchor moiety), 
combination of PfTRAP with liver stage antigen 1 (LSA1) & LSA2 were developed 
and tested for their efficacy [42]. The enhanced T-cell based response is the major 
advantage of this approach. Nonetheless, the efficacy of different candidate(s) 
found to be low in malaria endemic regions. Inclusion of more target specific 
immunogen(s) of Plasmodium and or combination with RTS,S may improve the 
overall efficacy.
The technological advancement in the field has helped the scientific community 
to understand host-pathogen interaction in detail. As a result of it, numerous new 
and improvised approaches come into practice for the successful vaccine develop-
ment. To review the status of vaccine candidates and accelerate the development of 
second generation malaria vaccines, several scientific meetings and forums [72, 73] 
were organized as well as provided the literature for the same [17, 55, 74, 75]. 
Therefore, here we have not discussed about all the different types of vaccines.
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In early 1980s, monoclonal Abs and recombinant-DNA approach have also been 
used for several antigens followed by their cloning and efficacy testing. However, 
the efficacy was tested only in experimental (in-vivo) settings and results were 
not up-to the mark [76]. From the beginning, most of the vaccine development 
has targeted LS of malaria infection. However, people have also focused on other 
target of life cycle known as BS (blood stage), another approach which can kill the 
asexual stage of parasites. During this symptomatic stage of infection, merozoites 
released from the LS invade the naïve RBCs, which is followed by its multiplication 
and infection of the surrounding RBCs. This stage of cycle persists from 1 to 3 days 
depending upon the Plasmodium species [74].
Targeting the blood stage for the vaccine development is equally important as 
malaria symptoms occurs during this stage and it has also gained interests as results 
of clinical studies have confirmed the clearance of parasites in African children 
[51, 77] and adults in Thailand [53] after the purification and passive transfer of 
IgG from semi-immune African adults and P. falciparum infected Thai-patients, 
respectively. In the early 1980s, trials were conducted on monkeys by using the 
P. falciparum fully developed merozoites armed with adjuvant followed by challenge 
with homologous strain of P. falciparum [78]. Except the control monkeys, all the 
immunized monkeys survived and generated the strong immune response. The 
promising findings of the study encouraged the community to focus on develop-
ment of vaccine based on blood stage resulting in more than 30 blood stage vaccine 
candidates that registered during 2000–2015 from the targets of the merozoites 
surface protein (MSP) 1 and apical membrane antigen 1(AMA-1). MSP 3 and eryth-
rocyte binding antigen 175 (EBA-175) are some of the other BS targets which were 
also explored to check the efficacy. The high titer Ab was observed against most 
of the MSP proteins; a protein express on merozoites which further invades RBCs, 
and Ab-mediated cellular inhibition was noticed during the clinical trial of MSP3 in 
malaria endemic area [79]. In sum, the results of pre-clinical and clinical studies of 
BS vaccine candidates suggest that they were unable to generate the strong evidence 
for the protection in controlled human malaria infection (CHMI) or in natural 
infection.
Similarly, in-vitro experiments of AMA-1 have been shown to generate elevated 
Ab titer in two trials, but during the clinical trials of CHMI it had failed to gener-
ate the sterile protection against the homologous strain of Plasmodium parasites 
[80, 81]. Out of all the BS vaccine candidates, only GMZ2 (combination of 
conserved domain of MSP and glutamate-rich protein-GLURP) have shown the 
statistically significant efficacy in controlled trial conducted in African children 
[82]; however, the efficacy was around 14%. To overcome the existing issues 
associated with poor immunogenicity, other candidate vaccines as well as novel 
therapeutic options are explored and some of them are currently in pipeline. As 
a result of it, P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) and 
AMA1-RON2 (rhoptry neck protein-2) complex are currently under experimental 
phases; early-stage results were found to be promising which may aid in designing 
the better vaccine candidate [74]. In defiance of optimistic results of BS vaccines, 
a narrow window period of merozoites which allow Abs to recognize and identify 
their epitopes during their infection cycle to RBCs (infected-to-naïve-to-infected), 
convoluted and complex invasion mechanism, polymorphic nature of Ags and 
simultaneously targeting a large number of merozoites in contrast to confined 
targets of LS and TBVs (transmission blocking vaccines) are the key questions 
which needs to be address at the earliest for the successful blood stage vaccine 
development.
Apart from LS and BS, researchers have also explored the third vaccine type, 
transmission-blocking vaccines (TBVs) comprising of sexual stage Ags (of gametes 
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and/zygotes) which generate the Abs and kill the parasites during the blood-meal 
of mosquitoes and result in the interruption of mosquito cycle [74]. Till date, there 
are four major candidates, Pfs230 and Pfs48/45 of P. falciparum (expressed by 
gametocytes in human) and Pfs25 and Pfs28 (zygote surface proteins expressed 
in mosquitoes) are under investigation. Due to the structural nature of these Ags 
(cysteine-rich armed with number of 6-cys), there has been a major concern to 
develop the stable recombinant protein; Pfs25 is the first recombinant protein based 
TBVs [83] and shown the encouraging results by equal or higher Ab titer against the 
target of transmission [84, 85]. Apart from this, Pfs230 another TBVs is also under 
clinical trials as it shows the strong lysis activity against the P. falciparum gametes 
in in-vivo system [86]. Both the recombinant Ag based TBVs have depicted the 
poor immunogenicity during their immunization strategy; to boost up the immune 
system, approach of administration of adjuvants and or combination of both candi-
dates together are explored and currently it is under trials [74]. Albeit the optimistic 
results in the early phase, safety of individuals, to cover the larger population for the 
herd immunity and prolonged adaptive immune response to maintain the higher Ab 
titer are the major challenges which need to be keep in mind for the development 
of next generation TBVs. Additionally, the combinational approach of LS and TBVs 
or BS stage and TBVs is also need to be explored to target multiple sites at a once 
[74]. Currently, the leading vaccine candidates for all the three different types are 
illustrated in below given Figure 3.
Figure 3. 
Life cycle stage of Plasmodium and vaccine candidates that target each stage (adapted with permission 
from [74]).
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2.1.2 RTS,S malaria vaccine: Learning lessons from gained knowledge
RTS,S (a recombinant protein based vaccine) was first developed by SmithKline 
Beecham Biologicals (now known as GlaxoSmithKline Vaccines) in the early 1980s, 
and has become the first ever licensed vaccine approved by European regulators to 
use against the human parasite infection in 2015 [87]. From the early experimental 
studies, modification has been adapted and the novel RTS,S is combined with AS01 
(a liposomal formulation) or AS02 (a emulsion based formulation) adjuvant system 
which trigger the toll-like receptor (TLR4) mediated cytokines and appropriate 
co-stimulatory signaling molecules on APCs. Additionally, it also activates both 
wings of the immune system against the CSP and able to generate sterile protection 
in Plasmodium challenge study, led it to enter in Phase III clinical trials [14]. In a 
phase III study, 829 cases were treated out of 1000 malaria affected children, yet 
it has unable to boost up the immune system in infants [88]. In another phase III 
study conducted on children and infants (age group of 1–4), 56% and 65% reduction 
was observed in case of severe malaria, respectively [89]. The selection of CSP Ag 
in RTS,S vaccine is derived from the earlier reports where approach of inactivated 
sporozoites has generated sterile protection and provoked immune response which 
was mediated by CSP-specific Abs and CMI. These CSP-specific Abs withhold the 
penetration of sporozoites into liver hepatocytes, still they are unable to achieve the 
sterile protection alone and therefore, RTS,S vaccine was designed by incorporating a 
CSP T-cell epitopes (CMI response) alongside the B-cell epitope [90]. The prominent 
role of CMI in generating sterile protection against malaria infection was noticed 
during the phase II clinical study, in which three different adjuvant formulations 
(AS02, AS03 and AS04) were explored, and only formulation i.e., RTS,S/AS02 was 
shown to invoke the sterile immunity after the P. falciparum challenge [90]. Later, 
more focused approach was developed towards the enrichment of CMI response 
which further helps in designing and selection of better adjuvant system to enhance 
the efficacy of RTS,S vaccine [91, 92]. Thus, RTS,S/AS02 was evaluated in field trials; 
after prolonged study, it has been replaced with earlier adjuvant of AS01 with higher 
efficacy, safety and elevated immunogenicity [91, 93–95]. Once the role of T-cell 
started revealing in terms of protection, several assays were developed to study the 
phenotypic characteristics and nature & involvement of different types of T-cells in 
malaria infection. Further, T-cell based response against the immunization of RTS,S 
has been verified in CHMI & field study and further also summarized in Table 1.
Later on, Strategic Advisory Group of Experts on Immunization (SAGE) of 
WHOs and Malaria Policy Advisory Committee (MPAC) have jointly recommended 
a pilot study for the vaccination in Africa; it has began in Malawi, Ghana and in 
Kenya between the April and October, 2019 [96]. Despite the approval of RTS,S 
vaccination, the issue of safety in children is well-documented and therefore, 
combination of different novel adjuvants with change in the length of CSP-specific 
peptides and structural information of CSP-specific Abs may further improve the 
efficacy of RTS,S vaccine [97]. Subsequently, a next generation vaccine was devel-
oped (R21) and accounted for the improvised version of RTS,S as it incorporates the 
longer portion of PfCSP C-terminal armed to N-terminal of HBs Ag. The elevated 
CSP-specific Ab response, higher immunogenicity at the lower doses (in in-vivo 
challenge study) and formulation with AS01 adjuvant resulted into beginning of 
clinical trials of phase 1/2a for its efficacy [42].
The development and efficacy of RTS,S vaccine in clinical trials and field study 
have confirmed the role of T-cell based sterile protection. Recent advancement 
in the field of genetics and structural biology has driven the area and again the 
older approach of whole parasite/sporozoite vaccine has been reintroduced to fulfill 
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with malaria episodes (p = 0.053)
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protection
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CMI conclusions from clinical studies (adapted and modified with permission from [90]).
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the criteria of generating long-lasting sterile protection with improved efficacy. 
Besides, radiation attenuated sporozoites (RAS) and genetically attenuated spo-
rozoites (GAPs) and attenuated sporozoites under the drug coverage (chemopro-
phylaxis and sporozoite-CPS) have recently gain the interest despite the various 
 difficulties [98].
2.2 Whole sporozoite vaccines
It has been well-documented that malaria life cycle begins with the invasion of 
hepatocytes (in liver) by sporozoites; if restrained its development to the LS, the 
immune responses to Plasmodium is developed. Usage of frontline-antimalarial 
prophylaxis to overcome the clinical manifestation or approach of attenuated 
parasites to arrest the life cycle at LS are the two availed options which have been 
explored in numerous ways (finding of specific immunogen(s) bearing B-and-T-
cell based epitopes, route of administration and dosage) to empower the humoral 
and CMI specific response [99]. Under the beneath of sporozoite approach, there 
are three different ways through which protective immune responses can be 
achieved [42].
2.2.1 Chemo- prophylaxis and sporozoites (CPS)
Under this approach, live sporozoites are delivered alongside the available 
anti-malarial drugs with the aim of targeting BS infection, generation of elevated 
humoral response and followed by understanding the LS infection. In this direc-
tion, the first study was conducted in mice under the cover of chloroquine (CQ ) 
and found to be protective with more number of CD8+IFN-γ+ T cells [100]. In 
the following years, the first human trial was conducted under the cover of CQ 
in CHMI and found to be 100% effective after homologous challenge, and more 
interesting, some of the volunteers remain immune for around 2 years [101]. 
The study of elevated immune response depicted the major role of memory T 
cells producing IL-2, TNF-α and IFN-γ. It has been noticed that higher dosage in 
homologous CHMI enhances the protection level. However, during the heterolo-
gous challenge study, protection was found to be remained limited, raising the 
question for its efficacy against the diversity of Plasmodium genus. The invention 
of novel antimalarial drugs have been explored, it has found and in one clinical 
study that usage of mefloquine (CPS-MQ ) also delineate the similar results of 
CPS-CQ in term of its efficacy and safety [102]. Additionally, all the volunteers 
(naive) having the CQ under CPS category are protected from homologous CHMI 
challenge [103]. Other than this, next generation anti-malaria drugs are under 
experimental phase.
2.2.2 Radiation attenuated sporozoites (RAS)
As mentioned earlier, mice immunized with x-ray irradiated sporozoites (P. 
berghei) were unable to develop LS infection and during the challenge study they 
were found to be protective in nature by homologs or P. vinckei challenge study. The 
higher doses of gamma rays have the direct impact on the LS infection. Additionally, 
the route of inoculation also plays a critical role in success of RAS immunization. As 
in-vivo study depicted that intravenous (IV) route is more suitable with compare to 
subcutaneous (SQ ) or intradermal (ID) route which needs 7–10 timers higher  
P. yoelii RAS for the protective immunity [14, 104]. Moreover, a study conducted in 
macaques showcased the superiority of IV route in inducing and generating liver-
resident P. falciparum specific T-cells [105]. In the clinical trials with PfSpz, all the 
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11 volunteers (immunized with irradiated mosquito’s sporozoites) were protected 
after the first round of homologous infection challenge whereas only 2 out 10 were 
able to generate the sterile immune response against the heterologous challenge 
[106]. It portrays the vital role of RAS approach in protection against the malaria 
infection, yet the issue of heterogeneity needs to be addressed. In another clinical 
trial of CHMI, around 64% of volunteers were protected against the homologous 
P. falciparum (3D7) challenge after 19 weeks. Further, volunteers showing no 
parasitemia were challenged after the final immunization (33 weeks later) with the 
heterologous strain (7G8) and approximately 83% have shown no parasitemia [107]. 
The results of PfSPZ (RAS) immunization confirm the limited long-lasting immune 
responses, although no significant increase was observed in CD4+ and CD8+ T cell 
after second or third immunization.
2.2.3 Genetically attenuated sporozoites (GAS)
To overcome the existing hurdles of RAS, novel approach of genetic manipula-
tion was explored in Plasmodium species which could prevent the transition from 
LS to BS infection without altering major changes. In this direction, differential 
gene expression study was carried out to identify the target gene(s) responsible 
for LS to BS transition and two genes, UIS3 and UIS4 (encodes for the protein in 
parasitophorousvacuole membrane), were selected for the genetic manipulation 
[108]. In mice having P. berghei infection, LS development was found to be delayed 
in a single knock-out gene study and gained the sterile protection upon challenge 
which was dependent upon CD8+ T cells [42]. Subsequently, it has been extended 
to double-knock out study and was found to induce stronger immune response by 
generating IFN-γ producing memory and effector CD8+ T cells that persist for a 
period of 6 months [109].
After the success of initial GAS study, several other genes (p36, p36(p52) and 
b9) were identified which were found to remain conserved in all the Plasmodium 
species. The different gene knock-out study in animal model demonstrated a similar 
immune response, yet development of parasites was also observed in some of them 
[42]. Subsequently, a novel gene named SAP1 (sporozoite asparagine-rich protein 
1) of P. yoelii was discovered and found to be important for the LS development. In 
gene knock-out study it has conferred the delay in LS development and long-lasting 
protection upon challenge with wild-type sporozoites [110]. Few other genes were 
also explored; In a comparative study with RAS which generally arrest the early 
LS infection, more efficient and prominent effector and memory T-cell pool was 
observed, due to the GAS approach that progress towards the late LS infection and 
may be more diverse range of Ags were present. This lead to the first clinical trial, 
and P. falciparum double knock-out (p52 and p36) gene was tested for its efficacy 
and safety. Despite the encouraging results, 1 out of 6 volunteers showed parasit-
emia [111]. Therefore, further development took place in GAS and triple knock-out 
genes (p52, p36 and sap1) of P. falciparum strain was used. There was no break-
through parasitemia, and higher Ab titer with elevated cytokine pool of IFN-γ, IL-2 
and TNF-α were observed in all the volunteers [112]. The positive outcome led to 
the development of another GAS vaccine with double knock-out (B9 & SLARP), 
and in the early phase of 1/2a it has shown poor-to-moderate immune response as 
only 3 out of 25 volunteers were found to achieve the sterile protection after the 
mosquito-bite challenge [113].
Despite the yin and yang of GAS in clinical studies, it has been considered as 
more accurate and doable approach with compare to RAS. Additionally, with the 
novel technology of CRISPR-Cas9, various attenuated sporozoites can be generated 
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which might be more immunogenic in nature and aid in generating stronger 
immune response.
All the different approaches of vaccine development strongly suggest the cor-
relation of T-cells and protection against malaria infection. And, therefore it may 
be a decisive player in enhancing the efficacy of vaccine. By keeping in mind the 
importance of T-cell, in the next section we have discussed the role of T-cell based 
immunity in all the stage of infection as well importance of it in developing T-cell 
based vaccines.
3. T-cell based immune response: A key player of vaccine development
From the very beginning, it has been well documented that T-cells play an 
important role in protection and generation of sterile immune response in malaria 
infection. Once the sporozoites enter into the host live and invade the hepatocytes, 
APCs process and present the Plasmodium peptides through MHC which result in 
the activation of CMI response (alongside humoral response), mainly CD4+ and 
CD8+ T cells. After the resolution of infection, all the immune sentinels undergo 
regulative apoptosis, except pool of memory cells. These Ag-experienced memory 
cells are crucial during the secondary infection of Plasmodium and specifically, 
liver-resident memory CD8+ T cells serve as a first line of defense [114]. Although 
certain studies have confirmed that induction and expansion of memory CD8+ T 
cells are not hampered by absence of helper CD4+ T cells, the memory CD8+ T cells 
developed under this condition are found to be short-lived [115]. Therefore, it infers 
that for long-lasting memory CD8+ T cells which control the malaria infection, aid 
of helper CD4+ T cells [116] and continuous exposure of Ag is required. Yet, the 
memory response against the malaria infection is bottleneck [115]. The TCR-MHC 
bearing peptide of Plasmodium interaction is also important in generating T-cell 
based response (memory pool) as polymorphic nature of residual anchor and 
supporting once of individual peptide may have an effect on TCR-MHC interac-
tion [114]. With the development of sophisticated technology, the role of T-cells in 
malaria infection in all the different stages has been revealed. As a result, various 
advancements have been made in the vaccine development.
3.1 T-cell response: In early stage of sporozoites
During the blood-meal of Anopheles mosquitoes, infected sporozoites enter into 
the host, and dermis under the layer of skin is the first place where they get exposed 
and then transverse through the blood vessels and reach to the liver. Therefore, 
Ab-mediated humoral response is largely important for the early stage of infec-
tion. However, experimental animal studies have revealed that most of the injected 
sporozoites remain in dermis for about 6 hrs and very few of them are able to find 
the way through blood vessels [117]. Although the DCs (dendritic cells) mediated 
capturing mechanism of sporozoite Ags is poorly understood, it has been confirmed 
that several sporozoites crosses the network of lymphatic vessels and skin-draining 
lymph node where they can persist for around 24 hr after the infection [117]. 
Therefore, it may be possible that circulating DCs (cDCs) present in skin initiate 
the T-cell induction against the sporozoites. And, it has been well known that live 
sporozoites are capable enough of generating CD8+ T cells response. Although the 
detailed mechanism is yet to be understood, arming the Ab-response by providing 
CD8+ and CD4+ T cells, CMI plays an important role in early detection and restrain-
ing the transition to LS infection.
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3.2 T-cell response: In pre-erythrocytic stage (LS)
In continuation of early stage infection, once the sporozoites reach to the liver, 
LS infection cycle initiates and through a cascade of mechanisms, numbers of 
schizonts are formed between the periods of 5–6 days. In-vivo experimental study 
has confirmed that mouse CD8+ T cells restrict the parasite development within 
the hepatocytes by recognizing MHC-I/peptide complexes presented by infected 
hepatocytes [118]. For this, perforation occurs in hepatocytes cell membrane is 
responsible which carry the perforin and granzymes (pro-apoptotic protease). It 
induces apoptosis and produces the reactive-oxygen species. Additional aid is also 
provided by liver macrophages and Kupffer cells that carry out the activity of Ag 
presentation as they face the sporozoites during their entry into the liver [119]. 
CD4+ and CD8+ T cells of CMI wing are crucial in generating sterile protection 
against malaria infection and it has been verified in several sporozoite-and subunit-
based vaccine approaches, though in case of human it has been documented only in 
human peripheral blood as it is challenging and difficult to prove for LS infection 
because of ethical concern [114]. Howbeit, recent study carried out in non-human 
primates has shown 100-fold higher T-cell response (specific to protective CD8+ 
T cells) in liver compared to peripheral blood [120]. Therefore, it is required to 
understand the detailed mechanism and role of CD8+ T cells in protection. Li et al., 
2016 have developed the human immune system bearing mice and studied the 
role of CD8+ T cells in human malaria. They have reported the direct link between 
the functional activities of PfCSP-specific CD8+ T cells and threshold achieved of 
protection against the malaria infection [121]. Several other in-vivo experiments 
have also shown the correlation between parasite-specific IFN-γ producing CD8+ 
T cells and protection achieved in clinical settings [114]. It suggests that CD4+ and 
CD8+ T cells produce IFN-γ which further enhances the activity of cytotoxic CD8+ 
T cells by elevating the Ag presentation through MHC-I. Moreover, the enhanced 
IFN-γ level activates other phagocytic immune sentinels, macrophages and NK cells 
to perform the tightly-regulated apoptosis. Throughout the protection mechanism, 
pool of numerous cytokines are released including IL-12 and IL-18 that are known 
to activate the CD8+ T cells in TCR-independent manner which can kill the parasites 
by a mechanism of nitric oxide (NO) production [122]. The prominent role of CD8+ 
T cells, aid of CD4+ T cells in humoral and CMI response, generation and activation 
of cytokines and other immune cells corroborate the significance of T-cell based 
vaccine development.
3.3 T-cell response: In blood stage (asexual/symptomatic stage)
The release of merozoite from schizonts confirms the beginning of erythrocytic 
stage, where they invade the naïve RBCs, convert into trophozoites and develop 
thousands of merozoites which are ready to burst from the infected RBCs (iRBCs) 
and target the new RBCs. Due to the lack of MHC molecules, iRBCs cannot perform 
the Ag presentation to T cells. However, it is believed that iRBCs bind to DCs and 
macrophages through the receptor-ligand (of parasite) interaction and after the 
maturation, most of the DCs migrate to the spleen where they present the Ag via 
MHC-molecules to the naïve –T cells [123]. The role of DCs in the generation of BS 
specific Ab is studied in animal models. Experimental evidences have shown the 
emerging role of novel T-cell population of γδ+ and αβ+ in the generation of IFN-γ 
responses that control the BS infection of P. falciparum [124]. Pombo et al., 2002 
have studied the role of immune system by injecting low-dosage of P. falciparum 
iRBCs to the volunteers followed by challenge [125]. They have shown that iRBCs 
generate the CD4+ and CD8+ T cell specific response to the BS infection. Further 
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characterization of T-cells confirms that majority of them are IFN-γ producing (not 
IL-4 or IL-10) and there was no-significant role/production of antibodies in protec-
tion [125]. It has led the foundation to understand the role of T-cell which is now 
equally important for BS protection.
3.4 T-cell response: Towards the blood stage sexual parasites
During the blood-stage asexual cycle, certain number of parasites come out from 
the RBCs cycle and develops into male and female gametocytes. Till date very little 
literature is available about the T-cell response against the gametocytes. The first 
study conducted in 1997 where purified P. falciparum gametocytes were injected 
into malaria-naïve individuals and found that activated CD4+ T cells response 
against the gametocytes in human PBMC is similar to the response observed in 
asexual stage [126], except the induction of γδ T-cells. In similar line, another study 
was carried out in which blood of acute (not severe) infection of P. vivax were fed to 
the Anopheles mosquitoes and observed the pro-and-anti-inflammatory cytokines 
[127]. The results of this study reveal that parasite in the blood samples with the 
elevated anti-inflammatory IL-10 (not IFN-γ or TNF-α) were unable to develop the 
infection in mosquitoes. To understand the mechanism of transmission-blocking, 
T-cells (from immunized spleen cells of vaccinated mice) were passively transferred 
to Balb/c mice via IV route followed by an infection; on day 3 post-infection, ability 
to transmit in mosquitoes was studied [128]. It showed the reduction in 95% of 
transmission, and the viability of gametocytes was found significantly lower in 
exflagellation compared to the controls. Although the mechanism behind trigger-
ing CMI response is unclear, authors predict that it could be cytokines or secretory 
products released by macrophages. This study unmasks the role of T-cells in early 
stage of BS infection wherein Ag-specific humoral response (Ab-based) comes 
latter into the picture and maybe help in the development of multi-target based 
vaccine.
The discovery of novel T-cell populations and their role in generating sterile 
protection alongside the conventional T-cells at each stage of malaria infection, aid 
the malaria biologist especially vaccinologists to design highly efficacious vaccine 
based on T-cells. Therefore, we have discussed about the different T-cells and their 
role in antigen diversity.
3.5 T-cell and their subtypes: Role in protective immunity against malaria
The induction of Plasmodium specific CD4+ T cells in protection against the 
malaria infection naturally or in different vaccination approach is well-documented 
[129]. As we know, the activated CD4+ T cells differentiate into several subtypes 
which largely depend upon on the cytokine environment. The differentiation of 
CD4+ T cells into Th1 is IFN-γ and IL-12 dependent, and the role of T-bet in Th1 dif-
ferentiation is also explored. The T-bet+Th1 IFN-γ producing cells express the MCSF 
(macrophage colony stimulating factor) that aid in controlling BS infection via 
macrophages. In addition to this, they also release IL-2 which can directly activate 
the NK cells which results into the direct killing of parasite infected cells. Having 
the multiple characteristics of Th1 cells, IFN-γ secreting Th1 cells directly/indirectly 
activate the potent CD8+ T cytotoxic cells via NO or higher expression of MHC-I 
on infected hepatocytes. In CHMI study, it has been found that the cytotoxic CD4+ 
T cells express CD107a, IFN-γ, CD38 and granzymes B, yet the mechanism of their 
activation is yet to be to be understood [129].
Th2, another set of CD4+ T cells that express transcription factor, GATA3 are 
characterized by production of IL-4 and IL-5. Although the role of Th2 in malaria 
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infection is poorly understood, IL-4 secreting Th2 cells have a major role in B-cell 
class switching [130] and macrophages activity [131] in malaria infection. In differ-
ent conditions of malaria infection, a population of T follicular helper (Tfh) cells 
is identified by the expression of chemokine receptor CXCR5, BCL-6 a transcrip-
tional factor and programmed cell death protein 1 (PD1)-a inhibitory receptor. The 
Plasmodium specific Tfh cells mainly express the ICOS and IL-21 which helps in 
maturation of germinal center (GC) and aid in production of plasma and memory 
B cells [129]. RNA-sequencing data have confirmed that Tfh cells development is 
IL-6 dependent and regulated by IRF3 during the BS infection [132]. The transition 
of Tfh cells to any other phenotypic subsets of CD4+ T cells is one of the interest-
ing phenomena which is required to be explored as it may drive the infection on 
either side. There are few studies depicted the presence of Th17 cells in Plasmodium 
infection that express the IL-17A. As no specific role of Th17 is found in malaria 
infection, IL-21 producing cells may help in GC activity and activation of CD8+ 
T cells, further it has shown that IL-22 producing Th17 cells regulate the inflam-
matory mechanism in lungs and liver of malaria infected rodent system [133]. 
Another CD4+ T cell, IL-27 producing CD4+ T cells, is having a dual character of 
pro-and-anti-inflammatory, and some of the reports have proposed their protective 
role in BS infection of malaria. Further it has been demonstrated that CD4+ T cells 
can also produce the IL-17 which do not express IL-10 and IFN-γ (CD4+ IFN-γ−IL-
10−T cells) [134]. Similarly, IL-10 producing CD4+ T cells and regulatory T cells 
(Treg) are two another sets of CD4+ T cells which demarcated by their cell surface 
proliferative markers, their role is found to be in favor of enhancing the malaria 
pathogenesis, although it is yet to be defined their precise action in different stages 
of infection.
As CD4+ T cells are important in generating strong immune response by activat-
ing humoral and CMI response, the role of CD8+ T cells in malaria pathogenesis, 
various subunit and whole sporozoites approaches and providing protection against 
the infection (more defined for LS infection) makes them the most desirable 
target for vaccine development. Among the different types of CD8+ T cells, role 
of liver-resident CD8+ T cells is indispensible alongside the effector and memory 
CD8+ T cells during the re-infection. Earlier studies depict the role of CD 11c+ DCs 
in priming the CD8+ T cells during the LS infection [116]. Later, newly identified 
population of monocytes (CD11b+CSF1R+CD207+F4/80+CD11c+) also found to be 
important in priming of CD8+ T cells, which strongly support the licensing activity 
of CD8+ T cells in the LS infection [129]. The mechanism of CD8+ T cell function in 
interrupting LS infection is found that Fas/FasL and granzymes are the two basic 
armed required for the effector function of CD8+ T cells which mainly produce 
TNF-α, IFN-γ and perforin [129].
Recently, a novel population of γδ T cells, is identified which comprises of less 
than 5% in adult human and its role in anti-malaria immunity is yet to be revealed. 
The earlier studies have confirmed the proliferation of them during the P. falci-
parum or P. vivax infection that correlate with protection [135]. Characterization 
of γδ T cells shows that during the phase of mild-to-acute infection, Vγ9+Vδ2+γδ 
T cells population increase which may further curtail down during the repetitive 
exposure of infection [129]. The reports of rodent model used for malaria infection 
revealed that γδ T cells do behave like other T-cells and they are found to be present 
in various tissues. Additionally, they also secrete IL-21, a required cytokines for Tfh 
cells [136] and as a result, it can function as a bridge for innate and adaptive immu-
nity. Their role is also found to be important in RAS immunization for effective 
function of CD8+ T cells via production of numerous cytokines. In an experimental 
study of P. chabaudi, during the BS infection a specific type of γδ T cells (Vγ6.3+γδ 
T cells) have been shown to undergo the clonal expansion and showcase the specific 
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phenotypic profile (with different transcriptional factors) which directly play a 
role in protection. Thus, it may aid in better understanding the pathogenesis and 
designing more efficient vaccine. In all, studying the different types of T cells and 
their role in individual stage of malaria infection will help in vaccine development. 
Despite the knowledge of T-cell mediated immunity, recently polymorphic natures 
of Plasmodium Ag(s) have shown the effect on T-cell response. Therefore, it is 
equally important to understand the impact of antigenic nature in generating sterile 
protection.
3.6 T-cell response: Effect of Plasmodium Ag(s) diversity
It has been studied that due to the polymorphic nature of Ag(s), effector func-
tion of CD8+ T cells and MHC-I peptide presentation become less prominent; as a 
result, during the secondary infection, it overcomes the immune system and estab-
lish LS infection [137]. Thus, with the help of sequencing technology conserved and 
variable epitopes of CSP and other potential target Ag(s) were found and reported 
[114]. Similar results were observed during RTS,S clinical trials, in which higher 
efficacy was observed in those children’s whose parasitic infection matches the 
T-cell based Th2R and Th3R epitope as compared the mismatched one [138]. It has 
been found in another gene based vaccine study that CD8+ T cells based response 
is restricted to HLA-I of AMA1 Ag of 3D7 strain but failed to act against the AMA1 
Ag of 7G8 strain that has the difference of only single amino acid [139]. It has been 
strongly supported by the earlier report of CSP where single amino acid replace-
ment have an impact on T-cell based immune response [140]. Thus, antigenic 
polymorphic nature and substitution of single/multiple amino acids in the epitopes 
may result in less interaction between T-cell peptide and MHC molecule causing the 
failure in generation of protective immunity.
3.7 T cells and vaccine development
The first licensed malaria vaccine RTS,S was designed by incorporating mainly 
B cell epitopes that induced humoral response. The Ab-mediated response may aid 
the induction of T-cells and evidence have shown the CD4+ T cells response, yet it is 
unable to understand that after RTS,S vaccination why immunity is remain short-
lived. It may possible that incorporation of appropriate CD8+ T cells based epitope 
which further enhance the sterile immunity. Additionally, it is also been interest-
ing to study the role of B cells in direct/indirect activation of CD8+ T cells. On the 
other hand, different approaches under the roof of whole sporozoite vaccine (CPS, 
RAS and GAS) depicted the prominent role of CD4+ and CD8+ T cells in protective 
responses against malaria infection in rodents, whereas in humans (under CHMI 
study) it has been limited to peripheral blood only. Additionally, among different 
subsets of T-cells which play a crucial role in providing protection and signaling 
pathway is yet to be fully understood. As mentioned earlier, injection of attenuated 
sporozoites through RAS approach have shown the antimalarial immunity against 
LS infection. Therefore, multiple antigenic targets of LS may help in generat-
ing strong liver-resident memory T cells. These WSV approaches have their own 
limitation and to prevail it, another approach of viral vector bearing Ag delivery 
has been explored and have shown the promising results [141]. After successful 
pilot study, to elicit the stronger T-cell based response several other options such as 
usage of nanoparticle based delivery system [142] and adeno-associated virus have 
been tried.
As T-cell mediated immunity is having prominent role in generating sterile pro-
tection, RAS and subunit vaccine approach which can induce stage-specific T-cell 
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immune response and restrain the LS infection should be considered. Recently, all 
the experimental evidence have demonstrated that instead of using single epitope 
based Ag, multiple-and-stage-specific epitopes of different Ag(s) can protect and 
generate stage-specific sterile response, yet it has to be verified in animal settings 
before going for the clinical trials. Also, poor immunogenicity of stage-specific 
Ag(s) required screening the whole genome database and available RNA-seq. data 
which can predict and identify (with matched HLA-typing) B-and-T-cell based 
epitopes to activate the immune response in a controlled manner. To overcome 
the current challenges mainly in T-cell based vaccine development below-listed 
novel approaches may aid in better results. Figure 4 depicted the major pathway of 




• High-throughput identification for immune protection
• Understanding the humoral and CMI response
• Selection of appropriate platform for vaccine development and delivery
4. Conclusion
Malaria still persists as a major global challenge and to fight against it several 
options have been explored. Despite the advancement in the field of technology, 
drug and insecticide resistance followed by recent threat of delayed clearance 
of parasite against the frontline of antimalarial(s) have created herculean situ-
ation. On the other hand, RTS,S is the only licensed vaccine against the malaria 
infection, which is also unable to reach the expectation in generating sterile 
protection. Significant role of T-cells (mainly CD4+ and CD8+ T-cells) is found to 
be a key-player against the malaria infection. To elicit the T-cell based response, 
novel approaches of vaccine development have been adopted and some of them 
Figure 4. 
(A) The major pathway of immune response and (B) at different stages of malaria infection how different 
immune cells can target malaria infected cells (adapted and modified from immunopaedia.org and [143–146]).
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are currently in pipeline of clinical trials. The older approach of WSV has recently 
gained the interest because of their potency to induce T-cell responses. The changes 
in RTS,S vaccine design via incorporating T-cell epitopes later on together with 
B-cells strongly support that finding of T-cell based multiple-epitope which can 
accelerate the immune response and aid Ab formation having immunogenicity in 
nature. By using the recent reverse vaccinology, structural based finding epitopes 
and predicted immunogen may aid in providing additional support in T-cell induc-
tion which are protective in nature.
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